DURECT (DRRX) Competitors

Immunic (NASDAQ:IMUX) and DURECT (NASDAQ:DRRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, community ranking, analyst recommendations and valuation.

Does the media prefer IMUX or DRRX?

In the previous week, Immunic had 6 more articles in the media than DURECT. MarketBeat recorded 16 mentions for Immunic and 10 mentions for DURECT. Immunic's average media sentiment score of 0.89 beat DURECT's score of -0.07 indicating that Immunic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunic	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
DURECT	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is IMUX or DRRX more profitable?

Immunic has a net margin of 0.00% compared to DURECT's net margin of -198.58%. Immunic's return on equity of -169.55% beat DURECT's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-169.55%	-118.96%
DURECT	-198.58%	-300.62%	-65.17%

Do analysts prefer IMUX or DRRX?

Immunic presently has a consensus price target of $12.67, suggesting a potential upside of 959.97%. DURECT has a consensus price target of $5.00, suggesting a potential upside of 525.00%. Given Immunic's stronger consensus rating and higher probable upside, equities analysts clearly believe Immunic is more favorable than DURECT.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.22
DURECT	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Do institutionals and insiders believe in IMUX or DRRX?

51.8% of Immunic shares are owned by institutional investors. Comparatively, 28.0% of DURECT shares are owned by institutional investors. 3.0% of Immunic shares are owned by company insiders. Comparatively, 3.2% of DURECT shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Which has better valuation and earnings, IMUX or DRRX?

DURECT has higher revenue and earnings than Immunic. DURECT is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$93.61M	-$1.23	-0.97
DURECT	$8.59M	2.89	-$27.62M	-$0.27	-2.96

Which has more risk & volatility, IMUX or DRRX?

Immunic has a beta of 1.89, suggesting that its share price is 89% more volatile than the S&P 500. Comparatively, DURECT has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500.

Does the MarketBeat Community favor IMUX or DRRX?

DURECT received 211 more outperform votes than Immunic when rated by MarketBeat users. However, 64.02% of users gave Immunic an outperform vote while only 61.72% of users gave DURECT an outperform vote.

Company	Underperform	Outperform
Immunic	Outperform Votes 105 64.02%	Underperform Votes 59 35.98%
DURECT	Outperform Votes 316 61.72%	Underperform Votes 196 38.28%

Summary

Immunic beats DURECT on 12 of the 18 factors compared between the two stocks.